Showing 831-840 of 5062 results for "".
- GUIDE: Guselkumab Dosing Every 16 Weeks Maintains Psoriasis Controlhttps://practicaldermatology.com/news/guide-guselkumab-dosing-every-16-weeks-maintains-psoriasis-control/2467730/Results from the GUIDE clinical trial showed that an extended dosing interval of guselkumab was effective for the treatment of moderate-to-sever plaque psoriasis. "Psoriasis is a chronic, systemic immune-mediated disease, predominately characterized by skin plaques, "the researchers wrote
- DART Releases New Clinical Guidelines for Nonmelanoma Skin Cancer Treatmenthttps://practicaldermatology.com/news/dart-releases-new-clinical-guidelines-nonmelanoma-skin-cancer-treatment/2467534/The Dermatology Association of Radiation Therapy (DART) has published new clinical guidelines for the treatment of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) using image-guided superficial radiation therapy (IGSRT), according to a news release. The guidelines, developed
- AQUA Dermatology Partners With First Coast Mohshttps://practicaldermatology.com/news/aqua-dermatology-partners-first-coast-mohs/2467290/AQUA Dermatology, backed by private-equity firms Gryphon Investors and GTCR, announced it now has 110 locations in the southeastern United States and more than 250 practitioners as a result of a new partnership with Jacksonville, Florida-based First Coast Mohs. First Coast Mohs will conti
- Report: Aesthetic Lasers Market to Surge 16.6% Annually Through 2032https://practicaldermatology.com/news/report-aesthetic-lasers-market-surge-166-annually-through-2032/2467086/Markets for aesthetic lasers are projected to $5.392 billion by 2032, according to a new report fro
- Adtralza Pre-Filled Pen Now Available for Canadian Atopic Dermatitis Patientshttps://practicaldermatology.com/news/adtralza-pre-filled-pen-now-available-canadian-atopic-dermatitis-patients/2467019/A new Adtralza® (tralokinumab injection) pre-filled pen has been made available for the first time in Canada for the treatment of moderate-to-severe atopic dermatitis (AD), according to a press announcement from LEO Pharma Inc. The single-use 2 mL pre-filled pen "simplifies the
- Humira Biosimilar Simlandi Now Available in the UShttps://practicaldermatology.com/news/humira-biosimilar-simlandi-now-available-us/2463126/Teva Pharmaceuticals and Alvotech announced the availability of Simlandi (adalimumab-ryvk) injection in the US as an interchangeable biosimilar to Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as adult rheumatoid arthritis, j
- Novel Species and Drug Resistance Found in Skin Infectionshttps://practicaldermatology.com/news/novel-species-and-drug-resistance-found-skin-infections/2463021/A recent study highlighted growing concerns within the dermatological community regarding an increase in treatment-resistant fungal strains. Researchers from The University of Texas Health Science Center at San Antonio focused their investigation on dermatophytes, a group of fungi respons
- Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and AD in Four Additional Countrieshttps://practicaldermatology.com/news/galderma-receives-filing-acceptances-nemolizumab-prurigo-nodularis-and-ad-four-additional-countries/2462968/
- Study: Potential for Combined Laser Treating Vascular and Pigmented Lesionshttps://practicaldermatology.com/news/combined-laser-shows-potential-vascular-and-pigmented-lesions/2462743/A novel laser with cryogen cooling long-pulsed options of both 532nm and 1,064nm laser offers laser surgeons a safe and effective way to treat vascular and pigmented lesions with a single device and significantly different clinical endpoints, wrote Nicole M. Golbari, MD, of the University of Cali
- FDA Issues Alert for Counterfeit Botox Across Multiple U.S. Stateshttps://practicaldermatology.com/news/fda-issues-alert-counterfeit-botox-across-multiple-us-states/2462747/The U.S. Food and Drug Administration (FDA) has issued an alert regarding counterfeit botulinum toxin that has been detected in several states. The agency issued a statement on April 16 noting that it is aware of the issue and is working with the Centers for Disease Control (CDC), state